罗莫佐单抗超级应答者:意大利多中心严重绝经后骨质疏松女性真实世界研究
该回顾性多中心研究纳入149例完成12个月罗莫佐单抗治疗的严重绝经后骨质疏松女性,评估真实世界疗效并识别超级应答(BMD增幅≥20%)的预测因素。腰椎平均BMD增幅+13.7%,18%为腰椎超级应答者;腰椎超级应答独立关联较高基线CTX、较大年龄和较低腰椎Z值,股骨颈超级应答关联既往股骨骨折。
要点
- 腰椎超级应答(≥20% BMD增幅)占17.8%,股骨颈占5.9%。
- 腰椎超级应答预测因素:较高基线CTX、较大年龄、较低腰椎Z值。
- 股骨颈超级应答与既往股骨骨折相关(OR 14.6,p=0.020)。
核心结论
- 罗莫佐单抗在真实世界严重绝经后骨质疏松女性中显示高效,相当比例患者获得高幅度BMD应答。
- 腰椎超级应答的独立预测因素为较高基线CTX、较大年龄和较低基线腰椎Z值;股骨颈超级应答与既往股骨骨折相关。
研究设计与样本
- 回顾性分析意大利五个中心完成12个月罗莫佐单抗治疗的绝经后女性,共149例,平均年龄69.4±9.9岁。
- 基线及治疗后行DXA扫描,收集临床病史、形态学和临床骨折及既往抗骨质疏松治疗史。
- 采用多因素logistic回归识别独立预测因素。
主要发现
- 腰椎平均BMD增幅+13.7%,股骨颈+5.9%,全髋+4.4%。
- 腰椎BMD增幅≥10%者占65.2%,股骨颈占17.8%,全髋占13.3%。
- 腰椎超级应答(≥20%)占17.8%,股骨颈占5.9%。
- 腰椎超级应答独立关联较高基线CTX(OR 1.42;p=0.018)、较大年龄(每岁OR 1.10;p=0.036)和较低基线腰椎Z值(OR 0.29;p=0.003)。
- 股骨颈超级应答关联既往股骨骨折(OR 14.6;p=0.020)。
关键数值与推荐
- “很好应答者”定义为BMD增幅≥10%;“超级应答者”定义为BMD增幅≥20%。
- 腰椎超级应答预测:较高基线CTX(OR 1.42;p=0.018)、较大年龄(每岁OR 1.10;p=0.036)、较低基线腰椎Z值(OR 0.29;p=0.003)。
- 股骨颈超级应答预测:既往股骨骨折(OR 14.6;p=0.020)。
临床怎么用
- 在严重绝经后骨质疏松女性中,罗莫佐单抗治疗12个月可获显著BMD提升,尤其腰椎。
- 基线CTX较高、年龄较大、腰椎Z值较低的患者更可能实现腰椎超级应答;有既往股骨骨折者更可能实现股骨颈超级应答。
局限性
- 回顾性设计。
- 样本量149例。
- 仅意大利五个中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Limited data on romosozumab super-responders. In 149 Italian women with severe osteoporosis, mean LS BMD gain was + 13.7%; 18% were super-responders (≥ 20%). PREDICTORS: high CTX/age/low Z-score for LS; prior femoral fracture for FN. Highlights site-specific response drivers in real-world setting. PURPOSE: To evaluate romosozumab effectiveness in a large Italian multicentre cohort of women with severe postmenopausal osteoporosis and identify predictors of high-magnitude densitometric response. Real-world evidence on romosozumab is expanding, yet data on high-magnitude response variability and clinical determinants of "super-responder" phenotypes remain limited. METHODS: Retrospective analysis of postmenopausal women who completed 12 months of romosozumab across five Italian centers. DXA scans were performed at baseline and after treatment. Data included clinical history, morphometric and clinical fractures, and prior anti-osteoporotic therapies. "Very good responders" were defined as ≥ 10% BMD gain; "super-responders" as ≥ 20%. Multivariate logistic regression identified independent predictors. RESULTS: 149 women (mean age 69.4 ± 9.9 years) were included. Prevalent vertebral (85.2%), femoral (30.9%), and non-vertebral (49.0%) fractures were common; 82% had prior therapy. Mean BMD gains were + 13.7% at lumbar spine (LS), + 5.9% at femoral neck (FN), and + 4.4% at total hip (TH). Very good responders (≥ 10%) occurred in 65.2% at LS, 17.8% at FN, and 13.3% at TH; super-responders (≥ 20%) in 17.8% at LS and 5.9% at FN. LS super-response was independently associated with higher baseline CTX (OR 1.42; p = 0.018), older age (OR 1.10 per year; p = 0.036), and lower baseline LS Z-score (OR 0.29; p = 0.003). FN super-response linked to prior femoral fracture (OR 14.6; p = 0.020). CONCLUSION: Romosozumab demonstrated high effectiveness in this real-world cohort, with a substantial proportion achieving high-magnitude BMD responses despite extensive prior treatment. Distinct site-specific predictors emerged: bone turnover and age/Z-score for LS, prior femoral fracture for FN.
引用
- Ghielmetti A, Grassi G, Carrara S, et al. Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis. Osteoporos Int. 2026. PMID: 41979842. doi:10.1007/s00198-026-07999-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。